Celcuity

Celcuity Financial Leverage

The Financial Leverage (Equity Multiplier) of Celcuity (CELC) as of Oct 2, 2026 is 4.64. In the previous year, Financial Leverage (Equity Multiplier) was 2.12 — a change of 118.85% (higher).

Financial Leverage

4.64

YoY

118.85%

Last updated:

Financial Leverage (Equity Multiplier) of Celcuity is 2026 4.64 . Financial Leverage (Equity Multiplier) of Celcuity was 2025 2.12 . It decreases by 118.85% higher compared to the previous year.

The Celcuity Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.03 USD
Jan 1, 2019
1.05 USD
Jan 1, 2020
1.11 USD
Jan 1, 2021
1.25 USD
Jan 1, 2022
1.31 USD
Jan 1, 2023
1.37 USD
Jan 1, 2024
2.12 USD
Jan 1, 2025
4.64 USD
The Celcuity Financial Leverage history
YEARFinancial LeverageYoY
4.64+118.85%
2.12+54.97%
1.37+4.16%
1.31+5.05%
1.25+12.92%
1.11+5.35%
1.05+2.34%
1.03+0.83%
1.02-5.65%
1.08+2.16%
1.06—
Access this data via the Eulerpool API

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

Financial Leverage (Equity Multiplier) of Celcuity is 4.64 in 2026.

Financial Leverage (Equity Multiplier) of Celcuity changed from 2.12 to 4.64, representing a 118.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Celcuity since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Celcuity with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Celcuity

All Key Metrics — Celcuity